Market cap
$113.4m
End-of-day close multiplied by current shares on issue.
RAD · NZX
Radius Residential Care (RAD)
Healthcare / Aged careCovered: FY23 - FY267 published briefings
Radius Residential Care is an NZX-listed healthcare / aged care company with FY23 - FY26 of published result briefings.
Sections
Snapshot
Latest metrics
FY26, released 13 May 2026
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $200.1m | ↑ +14.2% |
| EBITDA | $27.4m | ↑ +16.6% |
| NPAT | $9.5m | ↑ +35.7% |
| Operating cash flow | $25.1m | ↑ +25.3% |
| OCF / EBITDA % | 91.8%Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%. | ↑ +6.4pp |
| Net debt | $68.7m | ↑ +1.5% |
| Net debt / EBITDA | 2.51xOutside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x. | ↓ -13.1% |
| ROE % | 12.4%Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%. | ↑ +1.8pp |
| DPS | 1.2c | ↑ +50.0% |
| Payout ratio vs NPAT % | 66.1% | ↑ +10.3pp |
Source: latest published briefing (FY26, released 13 May 2026). Change compares against the prior equivalent period: FY25, released 21 May 2025.
Valuation
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
Prices as at close, 30 July 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
11.94x
Recent market cap compared with trailing earnings.
EPS
0.03
Recent filing-derived earnings per share.
PEG
0.33x
P/E compared with recent earnings growth.
EV/EBITDA
6.65x
Enterprise value compared with recent EBITDA.
P/FCF
12.53x
Market cap compared with recent free cash flow.
P/B
1.49x
Market value compared with latest reported equity.
Income and fund shape
Yield and fund-style valuation where the company shape supports it.
Dividend yield
5.5%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
P/E over time
Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.
Loading chart...
Chat
Ask about RAD
Ask follow-up questions about Radius Residential Care's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about RAD
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | FY2612 MONTHS13 May 2026 | HY266 MONTHS19 November 2025 | FY2512 MONTHS21 May 2025 | HY256 MONTHS25 November 2024 | FY2412 MONTHS29 May 2024 | HY246 MONTHS27 November 2023 | FY2312 MONTHS29 May 2023 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | $200.1m | $100.2m | $175.3m | $85.4m | $168.7m | $83.3m | $146.3m | Chart |
| Revenue growth % | 14.2% | 19.0% | 3.9%Outside range low revenue growth. 3.9%; 3-period range 10.8% to 15.4%. Revenue growth: 3.9%, below normal range; 3-period mean 13.5%, range 10.8%-15.4%. | 2.5% | 15.4%Outside range high revenue growth. 15.4%; 3-period range 3.9% to 14.2%. Revenue growth: 15.4%, above normal range; 3-period mean 9.6%, range 3.9%-14.2%. | 19.2% | 10.8% | Chart
|
| EBITDA | $27.4m | $14.9m | $23.5m | $9.6m | $20.9m | $10.5m | $14.2m | Chart |
| EBITDA margin % | 13.7%Outside range high ebitda margin. 13.7%; 3-period range 9.7% to 13.4%. EBITDA margin: 13.7%, above normal range; 3-period mean 11.8%, range 9.7%-13.4%. | 14.9% | 13.4% | 11.3% | 12.4% | 12.5% | 9.7%Outside range low ebitda margin. 9.7%; 3-period range 12.4% to 13.7%. EBITDA margin: 9.7%, below normal range; 3-period mean 13.2%, range 12.4%-13.7%. | Chart
|
| PBT | $14.3m | $8.5m | $10.5m | $2.8m | $3.6m | $1.6m | -$3m | Chart |
| PBT growth % | 36.2% | 203.6% | 191.7% | 75.0% | — | -27.3% | — | Chart |
| NPAT | $9.5m | $6.3m | $7m | $2m | -$8.5m | $1.4m | -$2.1m | Chart |
| NPAT growth % | 35.7% | 215.0% | — | 42.9% | — | -17.6% | — | Chart |
| Operating cash flow | $25.1m | $13.3m | $20.1m | $6.6m | $14.1m | $5.6m | $4m | Chart |
| OCF / EBITDA % | 91.8%Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%. | 89.3% | 85.4% | 68.5% | 67.4% | 53.6% | 28.4%Outside range low ocf / ebitda cash conversion. 28.4%; 3-period range 67.4% to 91.8%. OCF / EBITDA cash conversion: 28.4%, below normal range; 3-period mean 81.5%, range 67.4%-91.8%. | Chart
|
| FCF pre-lease | $9m | $9.6m | $13.7m | $3.7m | $10.6m | $3.7m | -$54.6m | Chart |
| DPS | 1.2c | 1.0c | 0.8c | 0.7c | 0.7c | — | — | Chart |
| Payout ratio vs NPAT % | 66.1% | 44.8% | 55.8% | 94.2% | — | — | — | Chart |
| Annual payout ratio vs EPS % | 66.1% | — | 55.8% | — | — | — | — | Chart |
| ROE % | 12.4%Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%. | 9.0% | 10.6% | 3.1% | -13.2%Outside range low roe. -13.2%; 3-period range -2.9% to 12.4%. ROE: -13.2%, below normal range; 3-period mean 6.7%, range -2.9%-12.4%. | 1.9% | -2.9% | Chart
|
| Net debt | $68.7m | $63.7m | $67.7m | $73.2m | $73.5m | $96.8m | $100.1m | Chart |
| Net debt / EBITDA | 2.51xOutside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x. | 4.27x | 2.89x | 7.59x | 3.51x | 9.26x | 7.05xOutside range high net debt / ebitda. 7x; 3-period range 2.51x to 3.5x. Net debt / EBITDA: 7.00x, above normal range; 3-period mean 2.97x, range 2.51x-3.50x. | Chart
|
| Debtor days | 21Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days. | 23 | 24 | 26 | 26 | 30 | 33Outside range high debtor days. 33d; 3-period range 21d to 26d. Debtor days: 32.6 days, above normal range; 3-period mean 23.6 days, range 21.2 days-25.6 days. | Chart
|
| Inventory days | 1Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days. | 1 | 1 | 1 | 1 | 2 | 2Outside range high inventory days. 2d; 3-period range 1d to 1d. Inventory days: 1.9 days, above normal range; 3-period mean 1.2 days, range 1.1 days-1.2 days. | Chart
|
| Total assets | $374.4m | $355.9m | $339.6m | $330.5m | $334.7m | $355m | $356.6m | Chart |
Reference: annolyse.ai/companies/rad
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
- FY24 RAD FY: Outside range high revenue growth. 15.4%; 3-period range 3.9% to 14.2%. Revenue growth: 15.4%, above normal range; 3-period mean 9.6%, range 3.9%-14.2%.
- FY25 RAD FY: Outside range low revenue growth. 3.9%; 3-period range 10.8% to 15.4%. Revenue growth: 3.9%, below normal range; 3-period mean 13.5%, range 10.8%-15.4%.
EBITDA-equivalent
Company-specific earnings measure where disclosed.
Loading chart...
EBITDA margin
EBITDA-equivalent margin where revenue and earnings are source-backed.
Loading chart...
- FY23 RAD FY: Outside range low ebitda margin. 9.7%; 3-period range 12.4% to 13.7%. EBITDA margin: 9.7%, below normal range; 3-period mean 13.2%, range 12.4%-13.7%.
- FY26 RAD FY: Outside range high ebitda margin. 13.7%; 3-period range 9.7% to 13.4%. EBITDA margin: 13.7%, above normal range; 3-period mean 11.8%, range 9.7%-13.4%.
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
Full chartable metric set
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
OCF / EBITDA
Cash conversion against earnings.
Loading chart...
- FY23 RAD FY: Outside range low ocf / ebitda cash conversion. 28.4%; 3-period range 67.4% to 91.8%. OCF / EBITDA cash conversion: 28.4%, below normal range; 3-period mean 81.5%, range 67.4%-91.8%.
- FY26 RAD FY: Outside range high ocf / ebitda cash conversion. 91.8%; 3-period range 28.4% to 85.5%. OCF / EBITDA cash conversion: 91.8%, above normal range; 3-period mean 60.4%, range 28.4%-85.5%.
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
ROE
Return on equity.
Loading chart...
- FY24 RAD FY: Outside range low roe. -13.2%; 3-period range -2.9% to 12.4%. ROE: -13.2%, below normal range; 3-period mean 6.7%, range -2.9%-12.4%.
- FY26 RAD FY: Outside range high roe. 12.4%; 3-period range -13.2% to 10.6%. ROE: 12.4%, above normal range; 3-period mean -1.8%, range -13.2%-10.6%.
Net debt
Borrowings less cash; negative values indicate net cash.
Loading chart...
Net debt / EBITDA
Leverage ratio, suppressed where earnings are not meaningful.
Loading chart...
- FY23 RAD FY: Outside range high net debt / ebitda. 7x; 3-period range 2.51x to 3.5x. Net debt / EBITDA: 7.00x, above normal range; 3-period mean 2.97x, range 2.51x-3.50x.
- FY26 RAD FY: Outside range low net debt / ebitda. 2.51x; 3-period range 2.89x to 7x. Net debt / EBITDA: 2.51x, below normal range; 3-period mean 4.46x, range 2.89x-7.00x.
DPS
Dividend per share declared for the period.
Loading chart...
Payout ratio
Dividend payout against statutory NPAT.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
- FY23 RAD FY: Outside range high debtor days. 33d; 3-period range 21d to 26d. Debtor days: 32.6 days, above normal range; 3-period mean 23.6 days, range 21.2 days-25.6 days.
- FY26 RAD FY: Outside range low debtor days. 21d; 3-period range 24d to 33d. Debtor days: 21.2 days, below normal range; 3-period mean 27.4 days, range 24.0 days-32.6 days.
Inventory days
Inventory days where the working-capital inputs are source-backed.
Loading chart...
- FY23 RAD FY: Outside range high inventory days. 2d; 3-period range 1d to 1d. Inventory days: 1.9 days, above normal range; 3-period mean 1.2 days, range 1.1 days-1.2 days.
- FY26 RAD FY: Outside range low inventory days. 1d; 3-period range 1d to 2d. Inventory days: 1.1 days, below normal range; 3-period mean 1.4 days, range 1.2 days-1.9 days.
Operating working-capital movement
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
Loading chart...
The setup & the reality
HY26 → FY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What HY26 said to watch
Previous analysisHY26Result releasedAnnolyse analysis published
From PBT up 204% on 19% revenue growth as cash conversion lifted to 89%
No quantified FY26 target is provided. Shape context shows HY25 represented only 48% of FY25 revenue and 28% of FY25 NPAT, so the historical pattern is second-half weighted. On that pattern alone, HY26 NPAT of $6.3m already sits close to the full FY25 NPAT of $7.0m, which sets a high bar for second-half delivery before the comparison can be considered conservative.
The release leans on Underlying EBITDA and EBITDAR-per-bed disclosures, with annualised EBITDAR per bed of $29.9k, but does not separate same-store growth from acquired or reconfigured beds. That gap matters because the durability of the operating leverage thesis depends on which mix is driving it.
Open questions
Open questions from HY26
- What drove the effective tax rate down to 22.3% from 28.6%, and is the lower rate structural or one-off?
- How much of the EBITDA uplift is same-store versus acquired or reconfigured beds, and what is the same-store occupancy trend?
- Given HY25 was only 28% of FY25 NPAT, is the historical second-half skew expected to repeat, or has the earnings shape now flattened?
- What is the target net debt to EBITDA range, and how does the capital-light growth strategy change future capex intensity above the current 3.7% of revenue?
- Why does the underlying EBITDA bridge still flag non-recurring items, and what residual adjustments sit between underlying and statutory earnings?
This briefing cannot assess occupancy, bed-level pricing, or wage and government-funding assumptions underpinning the EBITDAR-per-bed disclosure.
Archive
Briefing archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 13 May 2026
PBT up 36.2% and cash conversion at 91.8% as capex more than doubled
Underlying earnings ran above the historical baseline, but H2 NPAT roughly halved versus H1 as growth-strategy capex stepped up to NZ$16.1m.
Read briefing
HY26 · Released 19 November 2025
PBT up 204% on 19% revenue growth as cash conversion lifted to 89%
A lower effective tax rate flattered NPAT, but EBITDA +41% and leverage cut to 4.3x point to genuine operating gains.
Read briefing
FY25 · Released 21 May 2025
PBT rose 191.7% to $10.5m as margins and cash conversion stepped up
Margin and cash-conversion gains look durable, but a prior-year tax distortion exaggerates the NPAT swing from a $8.5m loss to a $7.0m profit.
Read briefing
HY25 · Released 25 November 2024
PBT up 75% but reported EBITDA fell 8.1% on a care home sale
Net debt cut 25% and cash conversion improved, but a 94.2% payout sits against a $0.07m cash balance and a higher tax rate.
Read briefing
FY24 · Released 29 May 2024
EBITDA up 47% but NPAT loss widened on tax distortion
Operating earnings and leverage improved sharply, but a 335.8% effective tax rate turned PBT of $3.6m into an $8.5m net loss.
Read briefing
HY24 · Released 27 November 2023
Asset sale puts Radius Residential Care's debt headroom in focus
The NZ$19m disclosed value from the asset sale is relevant to debt headroom, while borrowings and gearing remain the direct evidence.
Read briefing
FY23 · Released 29 May 2023
H2 EBITDA collapsed to $2.9m as net debt tripled to $100.1m
Debt-funded property purchases pushed leverage to 7.0x EBITDA while operating cash flow fell 59% and the result swung to a $2.1m loss.
Read briefing
Get notified when RAD publishes
Get the next Radius Residential Care result briefing and five-year history updates by email.